Healthpeak Properties offers a compelling 6.5% monthly dividend yield, supported by a BBB+ balance sheet and well-covered payout ratio. DOC trades at 10.65x forward FFO, well below its historical P/FFO of 14.0, presenting an attractive entry point after a recent dip. Outpatient medical and senior housing segments deliver steady results, while life science occupancy shows early signs of recovery amid sector headwinds.
Healthpeak's 6.
Healthpeak gets its prior buy from Oct. 2025 reaffirmed. Positives include a supportive macro environment, dividend coverage and high yield, an investment-grade rating, and leasing growth in Q2. Selective diversification is spread across outpatient, lab, and senior housing across a geographically diverse scale.
Healthpeak (DOC) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to DOC stock based on the movements in the options market lately.
Healthpeak Properties NYSE: DOC reported second-quarter adjusted funds from operations of $0.46 per share and raised its full-year adjusted FFO guidance by $0.02 to a range of $1.73 to $1.77 per share, citing improved same-store net operating income expectations in its lab and senior housing businesses.
Healthpeak Properties remains a Buy, supported by strong earnings, attractive dividend, and an ongoing portfolio pivot despite macro headwinds. DOC delivered a robust Q2, beating FFO and revenue estimates, increasing guidance, and executing $1 billion in asset sales to strengthen liquidity. Valuation remains compelling, with intrinsic value estimated above current levels even under conservative estimates, supported by conservative AFFO growth and a high discount rate.
Heathpeak tops Q2 FFO estimates as leasing gains and stronger senior housing results drive revenue growth and lift its 2026 FFO outlook.
Healthpeak Properties, Inc. (DOC) Q2 2026 Earnings Call Transcript
Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to FFO of $0.46 per share a year ago.
DOC is set to report Q2 results, with higher revenues expected as lab demand and senior care trends face pressure from interest expense.
Income investors entering July 2026 are getting a friendlier setup than they had six months ago.